These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 10646830)

  • 1. Dopamine receptor responsivity in schizophrenic patients before and after switch from haloperidol to risperidone.
    Markianos M; Hatzimanolis J; Lykouras L
    Psychiatry Res; 1999 Dec; 89(2):115-22. PubMed ID: 10646830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroendocrine serotonergic and dopaminergic responsivity in male schizophrenic patients during treatment with neuroleptics and after switch to risperidone.
    Markianos M; Hatzimanolis J; Lykouras L
    Psychopharmacology (Berl); 2001 Aug; 157(1):55-9. PubMed ID: 11512043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gonadal axis hormones in male schizophrenic patients during treatment with haloperidol and after switch to risperidone.
    Markianos M; Hatzimanolis J; Lykouras L
    Psychopharmacology (Berl); 1999 Apr; 143(3):270-2. PubMed ID: 10353429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dopamine receptor responsivity in schizophrenic patients in a drug-free state and after treatment with olanzapine.
    Lykouras L; Markianos M; Hatzimanolis J; Oulis P
    Prog Neuropsychopharmacol Biol Psychiatry; 2001 Apr; 25(3):507-18. PubMed ID: 11370994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia.
    David SR; Taylor CC; Kinon BJ; Breier A
    Clin Ther; 2000 Sep; 22(9):1085-96. PubMed ID: 11048906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Iodine-123-iodobenzamide SPECT assessment of dopamine D2 receptor occupancy in riperidone-treated schizophrenic patients.
    Dresel S; Tatsch K; Dähne I; Mager T; Scherer J; Hahn K
    J Nucl Med; 1998 Jul; 39(7):1138-42. PubMed ID: 9669383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prolactin responses to acute clomipramine and haloperidol of male schizophrenic patients in a drug-free state and after treatment with clozapine or with olanzapine.
    Markianos M; Hatzimanolis J; Lykouras L; Christodoulou GN
    Schizophr Res; 2002 Jul; 56(1-2):11-7. PubMed ID: 12084414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emotional experience and estimates of D2 receptor occupancy in psychotic patients treated with haloperidol, risperidone, or olanzapine: an experience sampling study.
    Lataster J; van Os J; de Haan L; Thewissen V; Bak M; Lataster T; Lardinois M; Delespaul PA; Myin-Germeys I
    J Clin Psychiatry; 2011 Oct; 72(10):1397-404. PubMed ID: 21208588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia: A Prospective Dopamine D2/3 Receptor Occupancy Study.
    Graff-Guerrero A; Rajji TK; Mulsant BH; Nakajima S; Caravaggio F; Suzuki T; Uchida H; Gerretsen P; Mar W; Pollock BG; Mamo DC
    JAMA Psychiatry; 2015 Sep; 72(9):927-34. PubMed ID: 26131622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Occupancy of dopamine D(1), D (2) and serotonin (2A) receptors in schizophrenic patients treated with flupentixol in comparison with risperidone and haloperidol.
    Reimold M; Solbach C; Noda S; Schaefer JE; Bartels M; Beneke M; Machulla HJ; Bares R; Glaser T; Wormstall H
    Psychopharmacology (Berl); 2007 Feb; 190(2):241-9. PubMed ID: 17111172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First generation antipsychotics switch with Risperidone in the treatment of chronic schizophrenic patients.
    Popović I; Ravanić D; Popović V; Vladejić S; Stanojević A; Stojanović M
    Psychiatr Danub; 2011 Dec; 23(4):384-8. PubMed ID: 22075740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Positron emission tomography measurement of dopamine D₂ receptor occupancy in the pituitary and cerebral cortex: relation to antipsychotic-induced hyperprolactinemia.
    Arakawa R; Okumura M; Ito H; Takano A; Takahashi H; Takano H; Maeda J; Okubo Y; Suhara T
    J Clin Psychiatry; 2010 Sep; 71(9):1131-7. PubMed ID: 20361897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: an international, multicenter study.
    Alptekin K; Hafez J; Brook S; Akkaya C; Tzebelikos E; Ucok A; El Tallawy H; Danaci AE; Lowe W; Karayal ON
    Int Clin Psychopharmacol; 2009 Sep; 24(5):229-38. PubMed ID: 19531959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma levels and estimated dopamine D
    Ikai S; Suzuki T; Mimura M; Uchida H
    Psychopharmacology (Berl); 2016 Dec; 233(23-24):4003-4010. PubMed ID: 27631410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risperidone in treatment-refractory schizophrenia.
    Wirshing DA; Marshall BD; Green MF; Mintz J; Marder SR; Wirshing WC
    Am J Psychiatry; 1999 Sep; 156(9):1374-9. PubMed ID: 10484947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia.
    Möller HJ; Riedel M; Jäger M; Wickelmaier F; Maier W; Kühn KU; Buchkremer G; Heuser I; Klosterkötter J; Gastpar M; Braus DF; Schlösser R; Schneider F; Ohmann C; Riesbeck M; Gaebel W
    Int J Neuropsychopharmacol; 2008 Nov; 11(7):985-97. PubMed ID: 18466670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The interaction between superoxide dismutase and prolactin is involved in response to haloperidol and risperidone treatment in schizophrenia: a double-blind and randomized study.
    Zhang XY; Zhou DF; Cao LY; Wu GY; Shen YC
    J Clin Psychopharmacol; 2006 Feb; 26(1):103-5. PubMed ID: 16415724
    [No Abstract]   [Full Text] [Related]  

  • 18. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients.
    Nyberg S; Eriksson B; Oxenstierna G; Halldin C; Farde L
    Am J Psychiatry; 1999 Jun; 156(6):869-75. PubMed ID: 10360125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate.
    Nyberg S; Farde L; Halldin C; Dahl ML; Bertilsson L
    Am J Psychiatry; 1995 Feb; 152(2):173-8. PubMed ID: 7840348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.